Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia
Status unconfirmed · Phase 4 · Has a placebo group
Conditions studied: Chronic Insomnia
In brief
This study aims to evaluate the effect of Suvorexant on sympathetic nerve activity and baroreflex function in subject with chronic insomnia. The investigator's central hypothesis is that Suvorexant will reduce sympathetic nerve activity and improve baroreflex function when compared to placebo.
Key facts
- Study ID
- NCT03768713
- Run by
- Montana State University
- People needed
- 34
- Starts
- 2019-04-18
- Expected to finish
- 2023-04-01
- Last updated by the study team
- 2021-10-07
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Minimum 3 months of clinically diagnosed insomnia
- Body mass index ≤35 kg/m2
- Insomnia Severity Index (ISI) > 7 arbitrary units (i.e., mild-to-severe insomnia)
- Pre-menopausal women must have regular menstrual cycles (\~26-30 day cycles) and will be scheduled for microneurography 2-7 days after menstruation to consistently test during the early follicular phase (or low-hormone phase in women on contraceptives)
You may not qualify if…
- Current or prior treatment of Suvorexant.
- Obstructive sleep apnea defined as an apnea-hypopnea index > 30 using an FDA approved home sleep apnea screening devices as used in routine clinical practice.
- Participants without evidence of clinically significant obstructive sleep apnea on the screening test will undergo an overnight in-laboratory polysomnography to confirm absence of sleep apnea (apnea-hypopnea index of ≥ 30 episodes per hour) and to exclude other sleep disorders (e.g. periodic limb movement arousal index of ≥ 5 episodes per hour)
- Circadian rhythm sleep disorders
- History of meeting DSM-V criteria of major psychiatric disorder
- Have been clinically-diagnosed with diabetes, cardiovascular disease, or any other unstable or serious medical condition.
- Current, or use within past month, of psychoactive (other than stable treatment with antidepressant or antianxiety), hypnotic, stimulant or analgesic medication (except occasional non-narcotic analgesics)
- Shift work or other types of self-imposed irregular sleep schedules
- Habitual smoking (6 or more cigarettes per week)
- Habitual alcohol consumption (more than 2 alcoholic drinks per day)
- Breastfeeding or pregnancy
Where it is running
- Montana State University — Bozeman, Montana, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.